The effect of co-administration of adjuvants with a nanoparticle-based genetic vaccine delivery system on the resulting immune responses

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 55, Issue 1, 2003, Pages 11-18

  Cui, Zhengrong ^a   Mumper, Russell J ^a  

^a University of Kentucky   (United States)

Author keywords

Cholera toxin; DNA vaccine; Immunization; Lipid A; Topical

Indexed keywords

CHOLERA TOXIN; CYTOKINE; DNA VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G; LIPID A; NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG DELIVERY SYSTEM; DRUG EFFECT; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; SPLEEN CELL;

EID: 0037240319     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0939-6411(02)00129-7     Document Type: Article

References (29)

1. Liu M.A., Hillerman M.R., Kurth R. DNA vaccines: a new era in vaccinology. Ann. N. Y. Acad. Sci. 772:1995;1-294.
2. Gurunathan S., Klinman D.M., Seder R.A. DNA vaccines: immunology, application, and optimization. Annu. Rev. Immunol. 18:2000;927-974.
3. Mumper R.J., Ledebur H.C. Jr. Dendritic cell delivery of plasmid DNA: application for controlled nucleic acid-based vaccines. Mol. Biotech. 19:2001;79-95.
4. O'Hagan D.T. Recent advances in vaccine adjuvants for systemic and mucosal administration. J. Pharm. Pharmacol. 49:1997;1-10.
5. Singh M., Briones M., Ott G., O'Hagan D. Cationic microparticles: a potent delivery system for DNA vaccines. Proc. Natl. Acad. Sci. USA. 97:2000;811-816.
6. Kazzaz J., Neidleman J., Singh M., Ott G., O'Hagan D.T. Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1. J. Control. Release. 67:2000;347-356.
7. Cui Z., Mumper R.J. Genetic immunization using nanoparticles engineered from microemulsion precursors. Pharm. Res. 19:2002;939-946.
8. Z. Cui, R.J. Mumper, Intradermal immunization with novel pDNA-coated nanoparticles via a needle-free injection device, AAPS Annual Meeting and Exposition, Toronto, Ontario, Canada, 2002.
9. Cui Z., Mumper R.J. Topical immunization using nanoengineered genetic vaccines. J. Control. Release. 81:2002;173-184.
10. Cui Z., Mumper R.J. Intranasal administration of plasmid DNA-coated nanoparticles results in enhanced immune responses. J. Pharm. Pharmacol. 54:2002;1195-1203.
11. Gupta R.K., Siber G.R. Adjuvants for human vaccines - current status, problems and future prospects. Vaccine. 13:1995;1263-1276.
12. Edelman R. Vaccine adjuvants. Rev. Infect. Dis. 2:1980;370-383.
13. Lycke N. The mechanism of cholera toxin adjuvanticity. Res. Immunol. 148:1997;504-520.
14. Glenn G.M., Rao M., Matyas G.R., Alving C.R. Skin immunization made possible by cholera toxin. Nature. 391:1998;851.
15. Hammond S.A., Tsonis C., Sellins K., Rushlow K., Scharton-Kersten T., Colditz I., Glenn G.M. Transcutaneous immunization of domestic animals: opportunities and challenges. Adv. Drug Del. Rev. 43:2000;45-55.
16. Glenn G.M., Taylor D.N., Li X., Frankel S., Montemarano A., Alving C.R. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat. Med. 6:2000;1403-1406.
17. Tang D., Shi Z., Curiel D.T. Vaccination on bare skin. Nature. 388:1997;729-730.
18. Gupta R.K., Relyveld E.H., Lindblad E.B., Bizzini B., Ben-Efraim S., Gupta C.K. Adjuvants - a balance between toxicity and adjuvanticity. Vaccine. 11:1993;293-306.
19. Sasaki S., Tsuji T., Hamjima K., Fukushima J., Ishii N., Kaneko T., Xin K., Mohri H., Aoki I., Okuo T., Nishioka K., Okuda K. Monophosphoryl lipid A enhanced both humoral and cell-mediated immune responses to DNA vaccination against human immunodeficiency virus Type 1. Infect. Immunol. 65:1997;3520-3528.
20. ®). Vaccine. 18:2000;1059-1066.
21. Sasaki S., Hamajima K., Fukushima J., Ihata A., Ishii N., Gorai I., Hirahara F., Mohri H., Okuda K. Comparison of intranasal and intramuscular immunization against human immunodeficiency virus type 1 with a DNA-monophosphoryl lipid A adjuvant vaccine. Infect. Immunol. 66:1998;823-826.
22. Fries L.F., Gordon D.M., Richard R.L., Egan J.E., Hollingdale M.R., Gross M., Silverman C., Alving C.R. Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc. Natl. Acad. Sci. USA. 89:1992;358-362.
23. Newman K.D., Samuel J., Kwon G. Ovalbumin peptide encapsulated in poly(d,l-lactic-co-glycolic acid) microspheres is capable of inducing a T helper type 1 immune response. J. Control. Release. 54:1998;49-59.
24. Wang D., Robinson D.R., Kwon G.S., Samuel J. Encapsulation of plasmid DNA in biodegradable poly(D,L-lactic-co-glycolic acid) microspheres as a novel approach for immunogene delivery. J. Control. Release. 57:1999;9-18.
25. Baldridge J.R., Crane R.T. Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines. Methods. 19:1999;103-107.
26. Kapsenberg M.L., Bos J.D. Skin, contribution to immunity. Roitt I.M., Delves P.J. Encyclopedia of Immunology. 1992;Academic Press, San Diego, CA.
27. Fan H., Lin Q., Morrissey G.R., Khavari P.A. Immunization via hair follicles by topical application of naked DNA to normal skin. Nat. Biotech. 17:1999;870-872.
28. Cui Z., Mumper R.J. Chitosan-based nanoparticles for topical genetic immunization. J. Control. Release. 75:2001;409-419.
29. Cui Z., Fountain W., Clark M., Jay M., Mumper R.J. Novel ethanol-in-fluorocarbon microemulsions for topical genetic immunization. Pharm. Res. 2002;. in press.